Effect of Fenofibrate on Plasma Lipoprotein Composition and Kinetics in Patients With Complete Hepatic Lipase Deficiency

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 25; no. 12; pp. 2600 - 2607
• Main Authors: Ruel, Isabelle L, Lamarche, Benoît, Mauger, Jean-François, Badellino, Karen O, Cohn, Jeffrey S, Marcil, Michel, Couture, Patrick
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01-12-2005; Hagerstown, MD Lippincott
• Subjects: Apolipoprotein A-I - blood; Apolipoprotein A-II - blood; Apolipoprotein B-100; Apolipoprotein E3; Apolipoproteins B - blood; Apolipoproteins E - genetics; Atherosclerosis (general aspects, experimental research); Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cardiovascular system; Cholesterol - blood; Cholesterol, LDL - blood; Cholesterol, VLDL - blood; Coronary heart disease; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Fenofibrate - administration & dosage; Heart; Heterozygote; Homozygote; Humans; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Hypolipidemic Agents - administration & dosage; Lipase - deficiency; Lipase - genetics; Lipoproteins - blood; Longitudinal Studies; Male; Medical sciences; Pharmacology. Drug treatments; Treatment Outcome; Vasodilator agents. Cerebral vasodilators; Human; lipids; genetics of cardiovascular disease; Digestive system; Enzyme; Fibrate derivatives; Deficiency; Liver; Triacylglycerol lipase; Cardiovascular disease; Esterases; Lipoprotein; Metabolism; Carboxylic ester hydrolases; Genetic disease; Vascular disease; Fenofibrate; Prevention; lipid and lipoprotein metabolism; Atherosclerosis; primary prevention; Hydrolases; Antilipemic agent
• ISSN: 1079-5642; 1524-4636
• DOI: 10.1161/01.ATV.0000190700.76493.bb

OBJECTIVE—The goal of this study was to characterize the effect of microcoated fenofibrate (160 mg/day for 6 months) on plasma lipoprotein composition and kinetics in 2 patients with complete hepatic lipase (HL) deficiency.
METHODS AND RESULTS—Fenofibrate treatment normalized the plasma lipoprotein profile of patients with complete HL deficiency, as evidenced by significant reductions in the plasma concentration of cholesterol (−49%) and triglycerides (−82%) and a significant increase in low-density lipoprotein (LDL) size (251.5±1.8 versus 263.5±0.7 Å). The in vivo kinetics of very low–density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL apolipoprotein (apo)B-100 and plasma apoA-I and apoA-II were studied using a primed-constant infusion of L-[5,5,5-D3]-leucine for 12 hours in the fasted state. Fenofibrate treatment in complete HL-deficient patients substantially decreased plasma concentrations of VLDL, IDL, and LDL apoB-100 attributable to important increases in VLDL (+325%), IDL (+129%), and LDL (+218%) apoB-100 fractional catabolic rates (FCR). IDL apoB-100 FCR nevertheless remained 60% lower after treatment compared with values obtained in controls (n=5). The kinetics of plasma apoA-I and apoA-II as well as the capacity of total plasma and of high-density lipoprotein particles to efflux cellular cholesterol from normal human skin fibroblasts was not altered by fenofibrate.
CONCLUSION—Fenofibrate therapy exerts a pronounced antiatherogenic effect on triglyceride-rich lipoproteins even in the complete absence of HL.